IL289769B2 - Single domain antibodies directed against intracellular antigens - Google Patents

Single domain antibodies directed against intracellular antigens

Info

Publication number
IL289769B2
IL289769B2 IL289769A IL28976922A IL289769B2 IL 289769 B2 IL289769 B2 IL 289769B2 IL 289769 A IL289769 A IL 289769A IL 28976922 A IL28976922 A IL 28976922A IL 289769 B2 IL289769 B2 IL 289769B2
Authority
IL
Israel
Prior art keywords
tnf
alpha
sdab
administration
subject
Prior art date
Application number
IL289769A
Other languages
English (en)
Hebrew (he)
Other versions
IL289769A (en
IL289769B1 (en
Original Assignee
Singh Molecular Medicine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singh Molecular Medicine Llc filed Critical Singh Molecular Medicine Llc
Publication of IL289769A publication Critical patent/IL289769A/en
Publication of IL289769B1 publication Critical patent/IL289769B1/en
Publication of IL289769B2 publication Critical patent/IL289769B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
IL289769A 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens IL289769B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US201562210795P 2015-08-27 2015-08-27
PCT/US2015/057223 WO2016065323A2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens

Publications (3)

Publication Number Publication Date
IL289769A IL289769A (en) 2022-03-01
IL289769B1 IL289769B1 (en) 2024-01-01
IL289769B2 true IL289769B2 (en) 2024-05-01

Family

ID=55761757

Family Applications (2)

Application Number Title Priority Date Filing Date
IL289769A IL289769B2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens
IL250961A IL250961B (en) 2014-10-23 2017-03-06 Monoclonal antibodies against intracellular antigens

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL250961A IL250961B (en) 2014-10-23 2017-03-06 Monoclonal antibodies against intracellular antigens

Country Status (24)

Country Link
US (4) US9663570B2 (enExample)
EP (3) EP3209685B1 (enExample)
JP (5) JP2017538671A (enExample)
KR (4) KR101831123B1 (enExample)
CN (2) CN106852148B (enExample)
AU (4) AU2015335600B2 (enExample)
BR (4) BR122020006907B8 (enExample)
CA (3) CA3114318A1 (enExample)
CY (2) CY1122035T1 (enExample)
DK (2) DK3209685T3 (enExample)
ES (2) ES2731876T3 (enExample)
HR (2) HRP20191056T1 (enExample)
HU (2) HUE047601T2 (enExample)
IL (2) IL289769B2 (enExample)
LT (2) LT3590962T (enExample)
MX (2) MX379450B (enExample)
PL (2) PL3209685T3 (enExample)
PT (2) PT3590962T (enExample)
RS (2) RS59063B1 (enExample)
RU (1) RU2017116710A (enExample)
SI (2) SI3209685T1 (enExample)
SM (2) SMT202100695T1 (enExample)
TW (1) TWI664289B (enExample)
WO (1) WO2016065323A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015335600B2 (en) 2014-10-23 2019-04-04 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
ES2913200T3 (es) 2015-03-31 2022-06-01 Sorriso Pharmaceuticals Inc Polipéptidos
CA2981098A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Peptide construct having a protease-cleavable linker
CA2981103A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
KR20180080189A (ko) 2015-09-01 2018-07-11 퍼스트 웨이브 바이오, 인코포레이티드 이상 염증 반응과 연관된 질환을 치료하기 위한 방법 및 조성물
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
US20190119259A1 (en) * 2015-12-10 2019-04-25 City Of Hope Cell penetrating cyanine-coupled antibodies
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3730150A4 (en) 2017-12-22 2021-10-06 Rophibio, Inc. ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
JP2021523115A (ja) * 2018-05-04 2021-09-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症性疾患または障害を治療するための方法および組成物
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
CN119684455A (zh) 2019-06-21 2025-03-25 索瑞索制药公司 多肽
AU2020294980A1 (en) 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3171066A1 (en) 2020-03-11 2021-09-16 Saar GILL Methods and composition for gene delivery using an engineered viral particle
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939B (zh) * 2021-04-14 2025-09-23 中山大学 一种融合蛋白及其制备方法与应用
JP2024525990A (ja) * 2021-07-07 2024-07-12 シン バイオテクノロジー、エルエルシー 単一ドメイン抗体によるブドウ膜炎の抑制
JP2024534833A (ja) * 2021-08-27 2024-09-26 シン バイオテクノロジー、エルエルシー 治療用単一ドメイン抗体
KR20240142411A (ko) 2021-12-15 2024-09-30 인테리우스 바이오테라퓨틱스, 인코포레이티드 위형 바이러스 입자, 이를 포함하는 조성물 및 이의 용도
WO2024003873A1 (en) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
CA3262768A1 (en) 2022-07-25 2024-02-01 Interius Biotherapeutics Inc Mutated polypeptides, compositions containing them, and their uses
AU2024215630A1 (en) 2023-02-04 2025-07-31 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
WO2025004683A1 (ja) * 2023-06-30 2025-01-02 国立大学法人大阪大学 がん検査方法及びがん治療剤
TW202521576A (zh) 2023-07-30 2025-06-01 美商健生生物科技公司 結合至突變型鈣網蛋白之分子及其用途
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
US20250376509A1 (en) 2023-11-21 2025-12-11 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004432A1 (en) * 2008-07-10 2010-01-14 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1994002610A1 (en) * 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
CA2378953A1 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US20040052762A1 (en) 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
CZ20031983A3 (cs) * 2000-12-29 2005-07-13 Savient Pharmaceuticals, Inc. Specifické protilátky pro selektivní léčbu rakoviny
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
AU2003285878B2 (en) * 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
BR122013001996B1 (pt) 2005-05-18 2022-02-01 Ablynx N.V. Nanocorpos melhorados contra fator alfa de necrose tumoral
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
US20100143371A1 (en) 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies
CA2588106A1 (en) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Single-domain antibodies and heavy chain antibody against egfr and uses thereof
EP2008666A1 (en) 2007-06-29 2008-12-31 Institut Pasteur Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications
US20110195509A1 (en) 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
CN102137658A (zh) * 2008-06-30 2011-07-27 斯兰斯德有限公司 局部递送药物的方法、组合物和系统
WO2010033913A1 (en) * 2008-09-22 2010-03-25 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
HK1204477A1 (en) * 2011-12-20 2015-11-20 阿达拉塔合伙有限公司 Single domain antibodies as inhibitors of pcsk9
PT2920308T (pt) * 2012-10-31 2019-03-20 Ionis Pharmaceuticals Inc Tratamento de cancro
WO2014144148A1 (en) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Stabilized sos1 peptides
US9802888B2 (en) * 2013-03-22 2017-10-31 University Of Hawaii STAT3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
CA2922698C (en) 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
EP2899208A1 (en) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
AU2015335600B2 (en) * 2014-10-23 2019-04-04 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004432A1 (en) * 2008-07-10 2010-01-14 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COPPIETERS, KEN, ET AL., FORMATTED ANTI–TUMOR NECROSIS FACTOR ALPHA VHH PROTEINS DERIVED FROM CAMELIDS SHOW SUPERIOR POTENCY AND TARGETING TO INFLAMED JOINTS IN A MURINE MODEL OF COLLAGEN-INDUCED ARTHRITIS, 30 May 2006 (2006-05-30) *
MORAIS, MAURICIO, ET AL., BIODISTRIBUTION OF A 67GA-LABELED ANTI-TNF VHH SINGLE-DOMAIN ANTIBODY CONTAINING A BACTERIAL ALBUMIN-BINDING DOMAIN (ZAG)., 30 May 2014 (2014-05-30) *

Also Published As

Publication number Publication date
IL289769A (en) 2022-03-01
US20160115244A1 (en) 2016-04-28
US9695234B2 (en) 2017-07-04
CA3052777C (en) 2021-06-01
IL250961B (en) 2022-02-01
PL3209685T3 (pl) 2020-01-31
WO2016065323A2 (en) 2016-04-28
CY1124867T1 (el) 2022-11-25
KR20190107199A (ko) 2019-09-18
KR20190108646A (ko) 2019-09-24
BR122020006907B1 (pt) 2022-03-22
EP3590962A1 (en) 2020-01-08
AU2019204614A1 (en) 2019-07-18
JP2020015732A (ja) 2020-01-30
KR20170070002A (ko) 2017-06-21
EP3209685B1 (en) 2019-04-24
AU2022204167A1 (en) 2022-06-30
WO2016065323A3 (en) 2016-06-16
JP6928773B2 (ja) 2021-09-01
TW201615834A (zh) 2016-05-01
US9546211B2 (en) 2017-01-17
BR112017008165B8 (pt) 2020-10-27
BR112017008165B1 (pt) 2020-04-22
RS59063B1 (sr) 2019-08-30
EP3209685A4 (en) 2018-01-24
ES2900253T3 (es) 2022-03-16
CN106852148A (zh) 2017-06-13
KR101831123B1 (ko) 2018-02-22
PT3209685T (pt) 2019-06-27
JP2022037002A (ja) 2022-03-08
PT3590962T (pt) 2021-12-15
HRP20191056T1 (hr) 2019-09-20
CY1122035T1 (el) 2020-10-14
BR122020006907B8 (pt) 2023-01-31
BR122020006918B8 (pt) 2023-01-31
HUE047601T2 (hu) 2020-05-28
IL250961A0 (en) 2017-04-30
KR20180021205A (ko) 2018-02-28
CA3114318A1 (en) 2016-04-28
MX379450B (es) 2025-03-11
EP3209685A2 (en) 2017-08-30
CA2962275A1 (en) 2016-04-28
TWI664289B (zh) 2019-07-01
CA2962275C (en) 2019-11-05
EP3590962B1 (en) 2021-09-29
KR102207381B1 (ko) 2021-01-27
JP2019142885A (ja) 2019-08-29
AU2021200416A1 (en) 2021-02-25
BR112017008165A2 (pt) 2018-03-06
BR122020006918B1 (pt) 2022-03-15
AU2021200416B2 (en) 2022-06-09
BR122020006914B8 (pt) 2023-01-31
BR122020006914B1 (pt) 2022-03-22
SI3209685T1 (sl) 2019-10-30
SMT202100695T1 (it) 2022-01-10
US9663570B2 (en) 2017-05-30
MX2021001098A (es) 2021-03-31
CN111848793B (zh) 2023-08-18
EP4006052A1 (en) 2022-06-01
JP6670963B2 (ja) 2020-03-25
HUE057605T2 (hu) 2022-06-28
SI3590962T1 (sl) 2022-02-28
US20160115248A1 (en) 2016-04-28
LT3590962T (lt) 2021-12-27
DK3209685T3 (da) 2019-07-29
AU2019204614B2 (en) 2020-10-22
RU2017116710A (ru) 2018-11-23
CN111848793A (zh) 2020-10-30
KR102023289B1 (ko) 2019-09-19
LT3209685T (lt) 2019-08-26
MX2017003268A (es) 2017-08-02
PL3590962T3 (pl) 2022-01-31
JP2017538671A (ja) 2017-12-28
AU2015335600A1 (en) 2017-03-16
DK3590962T3 (da) 2021-12-13
US20160115226A1 (en) 2016-04-28
AU2015335600B2 (en) 2019-04-04
HRP20211889T1 (hr) 2022-03-04
IL289769B1 (en) 2024-01-01
CN106852148B (zh) 2020-07-31
SMT201900413T1 (it) 2019-09-09
JP6986180B2 (ja) 2021-12-22
US20160115247A1 (en) 2016-04-28
JP2021165278A (ja) 2021-10-14
JP7195400B2 (ja) 2022-12-23
KR102207382B1 (ko) 2021-01-27
RS62694B1 (sr) 2022-01-31
CA3052777A1 (en) 2016-04-28
ES2731876T3 (es) 2019-11-19

Similar Documents

Publication Publication Date Title
IL289769B2 (en) Single domain antibodies directed against intracellular antigens
Zhang et al. Voltage-gated Na+ currents in human dorsal root ganglion neurons
Sanman et al. Disruption of glycolytic flux is a signal for inflammasome signaling and pyroptotic cell death
Xi et al. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion
Balu et al. Akt1 deficiency in schizophrenia and impairment of hippocampal plasticity and function
Perron et al. Early alterations in mitochondrial reserve capacity; a means to predict subsequent photoreceptor cell death
Hara et al. Calcium influx through a possible coupling of cation channels impacts skeletal muscle satellite cell activation in response to mechanical stretch
EA201992613A1 (ru) Фармацевтическая композиция, содержащая конструкции на основе биспецифического антитела, обеспечивающая улучшенное хранение и введение
JP2017538671A5 (enExample)
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
WO2011094467A3 (en) Methods of treating diabetes with dll4 antagonists
Mogilski et al. Aryl-1, 3, 5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide
Lipchik et al. A peptide-based biosensor assay to detect intracellular Syk kinase activation and inhibition
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
Coavoy-Sánchez et al. Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice
Bailey et al. Single quantum dot tracking reveals serotonin transporter diffusion dynamics are correlated with cholesterol-sensitive threonine 276 phosphorylation status in primary midbrain neurons
Yu et al. Flagellin/TLR5 responses induce mucus hypersecretion by activating EGFR via an epithelial cell signaling cascades
US11717508B2 (en) Compounds, compositions, and methods for inhibiting bacterial growth
Xin et al. USP10 alleviates palmitic acid-induced steatosis through autophagy in HepG2 cells
Lo et al. Effective activation by kynurenic acid and its aminoalkylated derivatives on M-type K+ current
Wu et al. Evidence for Inhibitory Effects of Flupirtine, a Centrally Acting Analgesic, on Delayed Rectifier K+ Currents in Motor Neuron‐Like Cells
Ding et al. Involvement of local serotonin-2A but not serotonin-1B receptors in the reinforcing effects of ethanol within the posterior ventral tegmental area of female Wistar rats
Pesarico et al. Contribution of NMDA, GABAA and GABAB receptors and l-arginine-NO-cGMP, MEK1/2 and CaMK-II pathways in the antidepressant-like effect of 7-fluoro-1, 3-diphenylisoquinoline-1-amine in mice
Shaifta et al. Divergent modulation of Rho‐kinase and Ca2+ influx pathways by Src family kinases and focal adhesion kinase in airway smooth muscle
Zhang et al. Descending vasa recta pericytes express voltage operated Na+ conductance in the rat